title: KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
abstract: Core binding factor (CBF) leukaemias, characterized by either inv(16)(p13.1q22) or t(8;21)(q22;q22), constitute acute myeloid leukaemia (AML) subgroups with favourable prognosis. However, 40-50% of patients relapse, emphasizing the need for risk-adapted treatment approaches. In this regard, studying secondary genetic aberrations, such as mutations of the KIT gene, is of great interest, particularly as they can be targeted by receptor tyrosine kinase inhibitors (TKI). However, so far little is known about the biology underlying KIT-mutated CBF leukaemias. We analysed gene expression profiles of 83 CBF AML cases with known KIT mutation status in order to gain novel insights in KIT-mutated CBF pathogenesis. KIT-mutated cases were characterized by deregulation of genes belonging to the NFkB signalling complex suggesting impaired control of apoptosis. Notably, a subgroup of KIT wildtype cases was also characterized by the KIT mutation signature due to yet unknown aberrations. Our data suggest that this CBF leukaemia subgroup might profit from TKI therapy, however, the relevance of the KIT mutation-associated signature remains to be validated prior to clinical implementation. Nevertheless, the existence of such a signature supports the notion of relevant biological differences in CBF leukaemia and might serve as diagnostic tool in the future.
authors.affiliation: Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23, Ulm, Germany.
authors.forename: Sonja C
authors.initials: SC
authors.lastname: Lück
authors.forename: Annika C
authors.initials: AC
authors.lastname: Russ
authors.forename: Juan
authors.initials: J
authors.lastname: Du
authors.forename: Verena
authors.initials: V
authors.lastname: Gaidzik
authors.forename: Richard F
authors.initials: RF
authors.lastname: Schlenk
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Pollack
authors.forename: Konstanze
authors.initials: K
authors.lastname: Döhner
authors.forename: Hartmut
authors.initials: H
authors.lastname: Döhner
authors.forename: Lars
authors.initials: L
authors.lastname: Bullinger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050660:Core Binding Factors / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009363:Neoplasm Proteins / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D015398:Signal Transduction / Q000235:genetics; D055815:Young Adult
chemical_list: D050660:Core Binding Factors; D009363:Neoplasm Proteins; D019009:Proto-Oncogene Proteins c-kit